Helixomer Inc., a cutting-edge drug development company co-founded by Professor Thom LaBean in 2020, has recently been honored with a $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health (NIH). This grant propels the preclinical development of Helixomer’s flagship products: an intravenous anticoagulant and its corresponding reversal agent, poised to compete in the expansive over $10 billion global heparin market.

Credit: Department of Materials Science and Engineering, NCSU 

More Information: https://mse.ncsu.edu/2023/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/